Skip to main content
. 2022 Aug 17;11(5):1917–1934. doi: 10.1007/s40121-022-00682-0

Table 5.

Potential risk factors for 30-day microbiological eradication in patients receiving CAZ/AVI- or PMB-based therapeutic regimens

Variable 30-day microbiological eradication P value
Success (n = 93) Failure (n = 71)
Age, years 64.4 ± 16.7 66.7 ± 12.2 0.328
Sex (female) 65 (69.9) 40 (56.3) 0.073
TBW, kg 64.8 ± 14.0 64.5 ± 12.9 0.887
Primary site of infection
 Primary bloodstream infection 13 (14.0) 9 (12.7) 0.808
 Respiratory infection 50 (53.8) 42 (59.2) 0.491
 Abdominal infection 14 (15.1) 15 (21.1) 0.312
 Urinary tract infection 11 (11.8) 4 (5.6) 0.173
 Other infections 5 (5.4) 1 (1.4) 0.236
Sepsis 37 (39.8) 22 (31.0) 0.245
Polymicrobial infection 13 (14.0) 12 (16.9) 0.606
APACHE II score (antimicrobial treatment onset) 16 (14–19) 17 (14–19) 0.975
CrCl, mL/min 67.0 (41.1–110.5) 61.5 (41.0–121.5) 0.828
CRRT 15 (16.1) 17 (23.9) 0.194
ECMO 1 (1.1) 1 (1.4) 1.000
Length of ICU stay before starting antimicrobial therapy, days 30 (15–61.5) 33 (20–50) 0.960
Vasoactive drugs 49 (52.7) 39 (54.9) 0.775
Mechanical ventilation 59 (63.4) 46 (64.8) 0.859
Comorbidities
 Cardiovascular disease 40 (43.0) 44 (62.0) 0.016
 Respiratory disease 43 (46.2) 31 (43.7) 0.743
 Central nervous system disease 21 (22.6) 17 (23.9) 0.838
 Autoimmune disease 7 (7.5) 8 (11.3) 0.410
 Liver disease 24 (25.8) 20 (28.2) 0.735
 Renal insufficiency 29 (31.2) 23 (32.4) 0.869
 Diabetes 26 (28.0) 13 (18.3) 0.150
 Organ transplantation 9 (9.7) 6 (8.5) 0.787
 Neoplasia 25 (26.9) 10 (14.1) 0.047
CCI score 5 (3–6) 4 (3–6) 0.860
Antimicrobial treatment duration (> 7 days) 83 (89.2) 39 (54.9) < 0.001
CAZ/AVI-based therapeutic regimens 66 (71.0) 16 (22.5) < 0.001
Antimicrobial combination therapy 63 (67.7) 46 (64.8) 0.691

All data are exhibited as number (%), mean ± SD, or median (interquartile range)